The Wistar Institute Cancer Center presents four Type I Shared Resources in this application: Animal Facility, Flow Cytometry, Imaging, and Protein Expression. During the past project period the Cancer Center made substantial investments in the Type I Shared Resources, utilizing over $7.2 million in capital funds and equipment grants for equipment upgrades and facility improvements. These Resources function as engines, integrated components ofthe research being conducted by Cancer Center members. The Type I Resources have demonstrated a significant impact to the scientific objectives ofthe Cancer Center, contributing to 172 of 382 (45%) of the unique cancer-related publications reported by the three scientific Programs. Following a comprehensive realignment of its Shared Resources by the appointment of dedicated leadership as described in the Cancer Center Administration section of this application, Shared Resources were grouped as Type I or Type II reflecting the intensity of collaborative input of their services. Type I Shared Resources provide critical and well-defined services that require an initial consultation followed by the delivery of time/format-defined services. Collaborative input for the type of service and data analysis is often required through consultation, yet such services generally achieve or are close in achieving full recovery of operating costs through chargebacks. Clear benchmarks and objective review criteria were introduced in order to enable timely oversight, scientific impact, quality of service, and financial strength for each Shared Resource. Regular evaluations of scientific impact for the Cancer Center (i) and sustainability of services (ii) for each resource guide the decision-making process for the Shared Resources. Overall Type I Shared Resources provide an essential cornerstone for research as their impact on discovery is inherent to the reliability, innovation, and state-of-the-art service platforms delivered.

Public Health Relevance

The deployment of state-of-the-art, technologically advanced scientific capabilities has become an indispensable requirement to conduct modern cancer research. Type I Shared Resources fulfill this need by providing well-defined, personalized service to Wistar Cancer Center investigators in support of their interprogrammatic and multidisciplinary research programs

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA010815-45
Application #
8690265
Study Section
Subcommittee G - Education (NCI)
Project Start
2014-03-01
Project End
2019-02-28
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
45
Fiscal Year
2014
Total Cost
$258,701
Indirect Cost
$116,941
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Saglam, Ozlen; Conejo-Garcia, Jose (2018) PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther 5:
Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426
Duperret, Elizabeth K; Trautz, Aspen; Stoltz, Regina et al. (2018) Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo. Cancer Res 78:6363-6370
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Bhattacharjee, Souvik; Coppens, Isabelle; Mbengue, Alassane et al. (2018) Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance. Blood 131:1234-1247
Fukumoto, Takeshi; Park, Pyoung Hwa; Wu, Shuai et al. (2018) Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep 22:3393-3400
Thangavel, Chellappagounder; Boopathi, Ettickan; Liu, Yi et al. (2018) Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. Clin Cancer Res 24:1402-1414

Showing the most recent 10 out of 741 publications